FABPs ligand 6 MF6|西域试剂

FABPs ligand 6 MF6,98.57%

产品编号：Bellancom-145990| 分子式：C₂₈H₂₇FN₂O₃| 分子量：458.52

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-145990	￥4000.00	杭州北京（现货）
Bellancom-145990	￥6800.00	杭州北京（现货）
Bellancom-145990	￥13500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FABPs ligand 6 MF6

产品介绍

FABPs ligand 6 (MF6) 是一种 FABP5 和 FABP7 抑制剂，K_D 值分别为 874 nM 和 20 nM。FABPs ligand 6 可用于多发性硬化症的研究。

生物活性

FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with K_D values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research.

体外研究

FABPs ligand 6 (MF6) rescues mitochondrial function by blocking voltagedependent anion channel (VDAC)-1-dependent mitochondrial macropore formation induced by psychosine in KG-1C cells, a FABP5- mediated injury.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

MF 6 (1 mg/kg; i.g.; daily for 4 weeks) improves the severity of EAE (experimental autoimmune encephalomyelitis) and attenuates oxidative levels and the inflammatory response.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-10-week-old female C57BMF/6J mice with MOG_35-55-administered experimental autoimmune encephalomyelitis (EAE) mouse model
Dosage:	1 mg/kg
Administration:	Intragastric administration, daily for 4 weeks
Result:	Attenuated EAE symptoms, decreased oxidative stress, inhibited astrocyte activation and protected oligodendrocytes.

体内研究

MF 6 (1 mg/kg; i.g.; daily for 4 weeks) improves the severity of EAE (experimental autoimmune encephalomyelitis) and attenuates oxidative levels and the inflammatory response.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8-10-week-old female C57BMF/6J mice with MOG_35-55-administered experimental autoimmune encephalomyelitis (EAE) mouse model
Dosage:	1 mg/kg
Administration:	Intragastric administration, daily for 4 weeks
Result:	Attenuated EAE symptoms, decreased oxidative stress, inhibited astrocyte activation and protected oligodendrocytes.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (272.62 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1809 mL	10.9046 mL	21.8093 mL
5 mM	0.4362 mL	2.1809 mL	4.3619 mL
10 mM	0.2181 mL	1.0905 mL	2.1809 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.54 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。